Zura Bio Limited (NASDAQ:ZURA) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of Zura Bio Limited (NASDAQ:ZURA) have been assigned an average rating of “Buy” from the seven ratings firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $15.80.

Several equities research analysts have recently commented on ZURA shares. HC Wainwright reissued a “neutral” rating and set a $5.00 target price on shares of Zura Bio in a research report on Tuesday, December 24th. Chardan Capital decreased their price objective on Zura Bio from $14.00 to $12.00 and set a “buy” rating for the company in a report on Friday, November 8th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zura Bio in a research report on Wednesday, December 11th. Leerink Partnrs raised Zura Bio to a “strong-buy” rating in a research report on Monday, November 4th. Finally, Leerink Partners began coverage on shares of Zura Bio in a report on Monday, November 4th. They set an “outperform” rating and a $15.00 price objective on the stock.

Zura Bio Stock Performance

Shares of NASDAQ:ZURA opened at $1.72 on Friday. Zura Bio has a 52-week low of $1.67 and a 52-week high of $6.35. The business’s 50 day simple moving average is $2.45 and its two-hundred day simple moving average is $3.44.

Zura Bio (NASDAQ:ZURA) last issued its earnings results on Thursday, November 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.12). On average, research analysts expect that Zura Bio will post -0.65 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Parvinder Thiara sold 1,001,633 shares of the firm’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $2.73, for a total transaction of $2,734,458.09. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 22.10% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Braidwell LP purchased a new position in Zura Bio in the third quarter valued at approximately $10,040,000. Point72 Asset Management L.P. purchased a new position in shares of Zura Bio during the 2nd quarter valued at $8,446,000. Great Point Partners LLC grew its stake in shares of Zura Bio by 68.3% during the 2nd quarter. Great Point Partners LLC now owns 4,642,241 shares of the company’s stock worth $16,248,000 after acquiring an additional 1,884,501 shares during the period. Armistice Capital LLC increased its holdings in Zura Bio by 53.2% in the 2nd quarter. Armistice Capital LLC now owns 2,524,000 shares of the company’s stock worth $8,834,000 after acquiring an additional 876,000 shares during the last quarter. Finally, Sphera Funds Management LTD. bought a new stake in Zura Bio in the 3rd quarter valued at about $2,999,000. 61.14% of the stock is owned by institutional investors.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.